TNFSF10 and B-cell chronic lymphocytic leukemia: To evaluate the potential therapeutic efficacy of combining HDACi with recombinant TRAIL for the treatment of B-CLL, we began by examining the ability of a panel of HDACi to upregulate TRAIL receptor expression on B-CLL.